Policy & Regulation: Page 23
-
PharmaVoice Team/PharmaVoice
Changing Oncology Regulations
Developing oncology therapies can be complex. These products often have a tough time making it to the market. In fact, a study released in February by the Biotechnology Industry Organization and BioMedTracker shows that oncology products had the lowest Phase III success rate among seven therapeut...
By Denise Myshko • May 24, 2011 -
PharmaVoice Team/PharmaVoice
Navigating the New Communications Landscape
The ways patients seek and share information—both in and out of the doctor’s office—are undergoing radical change. From the rise of the Internet to the explosion of social media to the growing patient demand for active participation in treatment decisions, a multitude of forces are converging to ...
By Chris DeAngelis • April 25, 2011 -
Explore the Trendline➔
Stock via Getty Images
TrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Be Successful in the New World of Accountable Care Organizations
In a few months, there will be a fundamental shift in how some Medicare providers operate with the beginning of the Medicare Shared Savings Program. In January 2012, Accountable Care Organizations (ACOs) identified by the U.S. secretary of Health and Human Resources will emerge that practice diff...
By Keith Mandia Senior Director • April 25, 2011 -
PharmaVoice Team/PharmaVoice
mHealth: Pharma's Next Blockbuster
The practice of mobile health, or mHealth as it is now known, has been around for decades. The first initiatives were designed to provide greater healthcare access to remote populations, mostly in developing countries. This trend continues and grows daily, providing many patients with a higher qu...
By PharmaVoice Team • April 25, 2011 -
PharmaVoice Team/PharmaVoice
The Era of Biosimilars
Although healthcare reform paved the way for a regulatory pathway for biosimilars, the biopharmaceutical industry is facing a world of uncertainty as developers and regulators navigate their way through this shifting landscape. Biosimilar Defined » A “biosimilar" is a biological product that i...
By Denise Myshko • March 29, 2011 -
PharmaVoice Team/PharmaVoice
What's New
The INSTITUTE OF CONTINUING HEALTHCARE EDUCATION and healthcare simulation technology developer HUMAN CONDITION HEALTH (HCH) are working together to develop learner-driven continuing medical education (CME) for healthcare professionals with a long-term focus on improving patient outcomes. Throug...
By PharmaVoice Team • March 28, 2011 -
PharmaVoice Team/PharmaVoice
Thought Leaders
Ryan Abbate. President, Pacific Communications, a healthcare communications agency that offers strategic and tactical communications solutions. For more information, visit pacific-com.com. Edward Abrahams, Ph.D. President,The Personalized Medicine Coalition, which brings together the academ...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
The End of the Arms Race
After more than a decade of crowding physicians’ offices with as many sales reps who would fit, the pendulum has swung dramatically in the other direction. The industry’s field ranks have been reduced dramatically, and now sales reps are crowding unemployment offices. Not just a Hired Gun Terren...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Everyone is Watching
The advent and growth of federal and state compliance regulations and the monitoring of those regulations have absolutely been game changers in the life-sciences industry over the last 10 years, says Peter Sandford, executive VP of NXLevel Solutions, a developer of technology-delivered learning a...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
The Patent Cliff
As companies look to fill the estimated $16 billion in annual revenue expected to be lost to generics over the next five years alone, they must become more adept at life-cycle management, pursuing viable reimbursement strategies, and developing evidence-based communications. If it seems as thoug...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
R&D Innovation: The Key to Long-Term Success
When the scientific discoveries and pipeline-building process of many successful biotechs are layered together, the results are likely to be dramatic. Experts predict there will be a number of game-changing product candidates in development in the next decade. “We view ourselves as part of the ‘m...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Agility: Key to Agency Success in the Future
For anybody involved in healthcare advertising, on the agency as well as the client side, the last decade has been marked by myriad changes and market factors that have impacted all aspects of the business. Client mergers and acquisitions, heightened regulatory scrutiny of messaging, more messagi...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Robert CUDDIHY Sanofi-Aventis Adds to Diabetes Team Sanofi-Aventis U.S. has appointed Robert Cuddihy, M.D., VP, medical diabetes head in the U.S. Dr. Cuddihy is responsible for developing and executing the U.S. medical affairs strategy for Sanofi-Aventis’s diabetes divisio...
By PharmaVoice Team • March 3, 2011 -
PharmaVoice Team/PharmaVoice
On the Calendar
March 21-22 BioConference Live: Life Sciences PharmaVOICE is exhibiting at this event. BioConference Live, bioconferencelive.com March 21-23 Digital Marketing & Communications for Canadian Pharma Toronto PharmaVOICE subscribers receive a $200 discount; register using keycode PharmaVOICE Adva...
By PharmaVoice Team • March 3, 2011 -
PharmaVoice Team/PharmaVoice
The Era of Proactive Safety
Process, people, and technology have to align to enable a truly proactive risk-management and pharmacovigilance program that protects patients. First, do no harm. This is medicine’s highest ethical standard, an oath physicians take when they begin to practice. In the last few years, dangerous s...
By Denise Myshko • Jan. 26, 2011 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Robert DAVIS Dr. Ludwig HANTSON Baxter International Forms Medical Products Business Baxter International has appointed Robert Davis corporate VP and president of its newly created medical products business, which combines the company’s renal and medication delivery businesses...
By PharmaVoice Team • Jan. 26, 2011 -
PharmaVoice Team/PharmaVoice
Healthcare Reform and Comparative Effectiveness
We all know that R&D focus, pharmaceutical promotion, pricing, and reimbursement are all, or will be, critically affected by the biggest U.S. healthcare reform to occur in 40 years. The impact is going to be disruptive, but overall, experts says it will be a positive gain for the pharmaceutic...
By PharmaVoice Team • Nov. 10, 2010 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 18-19 2nd Annual VA * DoD * PHS Federal Pricing and Contracts for Bio/Pharmaceutical Companies Courtyard Philadelphia Downtown, Philadelphia PharmaVOICE subscribers receive $400 discount; register using keycode RGR396. Center for Business Intelligence, cbinet.com November 18-19 West Coa...
By PharmaVoice Team • Nov. 9, 2010 -
PharmaVoice Team/PharmaVoice
Effective Global Teams Are Aligned, Not Built
Trust, understanding, common goals and perceptions, speaking the same language —literally and figuratively — all sound like the ingredients for a successful marriage. The same factors that are inherent in any successful relationship must be present among the members of global cross-functiona...
By PharmaVoice Team • Sept. 29, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Timothy HAYES Bayer Adds Global Business Development Oversight Timothy Hayes, currently senior VP and region head for Bayer HealthCare’s Consumer Care division in North America, has assumed the additional responsibility of leading the business unit’s global business developmen...
By PharmaVoice Team • Sept. 28, 2010 -
PharmaVoice Team/PharmaVoice
The REGULATORS
The fight against counterfeit drugs has an eminent champion in Paul Orhii, M.D., Ph.D., J.D. As director-general of Nigeria’s regulatory body, the National Agency for Food and Drug Administration and Control (NAFDAC), and in his role as vice chairman of the World Health Organization’s Internation...
By PharmaVoice Team • July 28, 2010 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: Augme Expands Mobile Health Division Service Combines Wolters Kluwer’s Scientific Writing, Publishing Expertise Compass Healthcare Marketers Focuses on Full Marketing Package FDA Task Force Seeks Public Input on Proposed D...
By PharmaVoice Team • July 28, 2010 -
PharmaVoice Team/PharmaVoice
Who's on the List by Company
Anavex Life Sciences Cameron Durrant, M.D. 18 ApotheCom David Dunn 16 Astellas Pharma US Margaret Long 73 AstraZeneca David Brennan 46 bioCapture Johanna Allston, Ph.D. 12 C3i Robert Piwko 112 Cegedim Dendrite Angela Miccoli 74 Cipla Ltd. Yusuf Hamied, Ph.D. 19 ClearTrial Mike Soenen 29 closerloo...
By PharmaVoice Team • July 28, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The PharmaVOICE 100: 2010 Every year, I think this is it, we’ve reached the pinnacle. And yet, every year, I continue to be amazed by the individuals whom our readers have identified as the most inspiring, motivating, and outstanding leaders in the life-sciences industry. This special issue, n...
By Taren Grom • July 28, 2010 -
PharmaVoice Team/PharmaVoice
ACRP 2010 Global Conference & Exhibition Wrap Up
The Association of Clinical Research Professionals (ACRP) remains steadfast in its mission to provide value and excellence to conference participants against a backdrop of continued economic and regulatory challenges to individuals and businesses. This year’s conference featured 55 sessions and 2...
By PharmaVoice Team • May 27, 2010
Previous
